NeuroDex to Present Neuron-Derived Extracellular Vesicle Biomarker Data at ADPD 2026

Dr. Erez Eitan will present two posters on plasma nEV biomarkers for TDP-43 pathology and synucleinopathy using the ExoSORT platform at the world’s leading Alzheimer’s and Parkinson’s disease conference.

NeuroDex is proud to announce that Dr. Erez Eitan, Chief Executive Officer and Chief Scientific Officer, will present two scientific posters at the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases. This prestigious conference brings together the world’s leading researchers and clinicians in neurodegenerative disease, making it an ideal venue for NeuroDex to share the latest advances in neuron-derived extracellular vesicle (nEV) biomarker research.

Poster Presentations at AD/PD 2026

Dr. Eitan will present new data from two studies leveraging the NeuroDex ExoSORT platform — a proprietary technology for the isolation and analysis of neuron-derived extracellular vesicles from blood plasma:

• Plasma Neuron-Derived Extracellular Vesicles as Biomarkers of TDP-43 Pathology — This study explores the potential of plasma nEVs to detect and monitor TDP-43 proteinopathy, a hallmark of ALS and frontotemporal dementia (FTD), offering a non-invasive window into disease-specific pathological changes in the brain.
• Plasma Neuron-Derived Extracellular Vesicles as Biomarkers of Synucleinopathy — This study presents findings on nEV-based biomarkers for synucleinopathies, including Parkinson’s disease, Lewy body dementia, and multiple system atrophy — conditions defined by the pathological aggregation of alpha-synuclein.

The NeuroDex ExoSORT Platform: Advancing Liquid Biopsy for the Brain

The NeuroDex ExoSORT platform enables the selective isolation of neuron-derived extracellular vesicles directly from peripheral blood. By capturing vesicles of neuronal origin, ExoSORT provides a unique, non-invasive approach to measuring CNS-specific biomarkers — bridging the gap between brain pathology and accessible clinical diagnostics. These findings highlight ExoSORT’s potential to transform early detection, patient stratification, and therapeutic monitoring in neurodegenerative diseases.

Why Neuron-Derived EV Biomarkers Matter

Neurodegenerative diseases such as Parkinson’s disease, ALS, and frontotemporal dementia remain challenging to diagnose and monitor, often due to a lack of reliable, accessible biomarkers. Neuron-derived extracellular vesicles — nano-sized particles released by neurons into the bloodstream — carry molecular cargo that reflects the state of the cells from which they originate. This makes them powerful candidates for liquid biopsy-based diagnostics, capable of detecting disease-specific proteins such as TDP-43 aggregates and alpha-synuclein pathology through a simple blood draw.

Meet NeuroDex at AD/PD 2026

We warmly invite conference attendees, clinicians, researchers, and collaborators to visit Dr. Eitan during the poster sessions in the Poster Area. Our team would be delighted to discuss our findings, share insights on the ExoSORT platform, and explore potential collaborations.

To schedule a dedicated meeting with Dr. Eitan or the NeuroDex team at AD/PD 2026, please contact us via our website or reach out directly. We look forward to connecting with the global neuroscience community.

About NeuroDex

NeuroDex is a clinical-stage biotechnology company developing blood-based diagnostic tools for neurodegenerative diseases. Using its proprietary ExoSORT platform, NeuroDex isolates and analyzes neuron-derived extracellular vesicles from plasma to detect disease-specific biomarkers with high sensitivity and specificity. The company’s mission is to enable earlier diagnosis, better patient stratification, and improved therapeutic development for diseases such as Alzheimer’s, Parkinson’s, ALS, and FTD.